• Benjamin Belot joined Kurma as Partner to add its experience in digital health to the team

• Hadrien Bouchez and Amine Marouf are promoted to Principals to acknowledge their contribution to the development of the firm
 

Kurma Partners, a leading European venture capital company in the field of Life Sciences based in Paris and Munich, today announced the appointment of Benjamin Belot as Partner and the promotion of Hadrien Bouchez and Amine Marouf as Principals.

Benjamin Belot, 36, has been appointed as Partner. He will join the Kurma Diagnostics 2 fund’s investment team on its first closing at 50 million euros. Prior to joining Kurma Partners, Benjamin created and led for 4 years digital health investments for Zuellig Pharma, a major health service provider in South-East Asia from Singapore. From 2012 to 2014, Benjamin served as Senior Business Intelligence Analyst at Janssen (Johnson & Johnson group) where he managed the entire oncology product portfolio. He previously advised clients from the pharmaceutical, diagnostic and medical devices industries in their innovation strategy at Alcimed. Benjamin holds a Master’s Degree in Chemical Engineering from the Ecole Nationale Supérieure de Chimie in Paris and an MBA from the INSEAD graduate business school.

Hadrien Bouchez, 32, is promoted to Principal. Hadrien joined Kurma Partners in 2014 as an Analyst before being promoted as Associate in 2017. Since then, he has participated in a dozen investments of the Kurma Biofund II and III funds. Hadrien has actively contributed in particular to the creation of several portofolio companies such as Dynacure, Imcheck Therapeutics, Flamingo Therapeutics, Ermium Therapeutics and Corlieve Therapeutics. Hadrien holds a PharmD from the Faculty of Pharmacy, Lille, and a Master in Entrepreneurship from the ESSEC Business School.

Amine Marouf, 35, is promoted to Principal. Amine joined Kurma Partners in 2017 as an Associate. Previously, Amine advised many healthtech companies in their strategy, fund raising and M&A as a consultant for Advitech from 2011 to 2015. Amine has actively contributed to the development of Kurma Diagnostics’ portfolio by identifying investment opportunities and structuring financing. He holds a European Magistere in Genetics from the Paris University and graduated from the ESSEC Business School.

Kurma Partners is thrilled to see a new member, Benjamin, coming onboard and to promote two of its youngest and most promising talents, Hadrien and Amine. Kurma Partners is more than ever active in supporting entrepreneurs and medical innovation with its new funds Kurma Biofund III (final closing at 160 million euros) and Kurma Diagnostics II (first closing at 50 million euros).